title: Tumor angiogenesis and biologic markers in resected stage I NSCLC.
abstract: OBJECTIVE
  Microvessel count (MC), as a measure of tumor angiogenesis, has been shown to be significantly correlated with metastatic disease in cutaneous, mammary, prostatic, head and neck cancer. We have previously assessed the role of intensity of angiogenesis as predictor of metastasis in surgically resected T1N0M0 NSCLC. We needed to confirm its value, in a prospective larger study on Stage I NSCLC, before its utilization as a prognostic tool for further clinical investigations.
  
  
  METHODS
  In the present report we prospectively investigated 227 patients (206 males, 21 females; median age 65 years) with Stage I NSCLC treated only by radical surgery between March 1991 and December 1994 with utmost care for some biological characteristics (proliferative activity, the blood vessel invasion, angiogenesis and the p53 protein expression).
  
  
  RESULTS
  The operative procedures consisted of 62 pneumonectomies, 148 lobectomies and 17 segmentectomies or wedge resections. With a median follow-up of 36 months (range 15-60), eighty patients have already experienced a local (n = 22) or systemic (n = 58) relapse. Univariate analysis revealed that T factor (T1 versus T2)(P = 0.008) and angiogenesis count (< or = versus > median, 17) (P = 0.0006) were significant predictors of survival. The same variables were also significant predictors of long Disease Free Survival (P = 0.006 and P = 0.004, respectively). On multivariate analysis, however, only the microvessel count retained its level of prognostic significance as regards both overall (P < 0.01) and disease-free survival (P < 0.01).
  
  
  CONCLUSIONS
  The present study corroborates the role of angiogenesis in the metastatic spread of NSCLC and emphasizes its value in the identification of patients in whom surgery should be supplemented by systemic treatment.
authors.affiliation: Department of Surgery, University of Pisa, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Lucchi
authors.forename: G
authors.initials: G
authors.lastname: Fontanini
authors.forename: A
authors.initials: A
authors.lastname: Mussi
authors.forename: S
authors.initials: S
authors.lastname: Vignati
authors.forename: A
authors.initials: A
authors.lastname: Ribechini
authors.forename: G F
authors.initials: GF
authors.lastname: Menconi
authors.forename: G
authors.initials: G
authors.lastname: Bevilacqua
authors.forename: C A
authors.initials: CA
authors.lastname: Angeletti
mesh_terms: D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis*; D002289:Carcinoma, Non-Small-Cell Lung / Q000098:blood supply* / Q000401:mortality / Q000556:secondary / Q000601:surgery; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008168:Lung / Q000098:blood supply / Q000378:metabolism; D008175:Lung Neoplasms / Q000098:blood supply* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D008297:Male; D009367:Neoplasm Staging; D009389:Neovascularization, Pathologic / Q000473:pathology*; D011379:Prognosis; D011446:Prospective Studies; D016159:Tumor Suppressor Protein p53 / Q000032:analysis*
chemical_list: D014408:Biomarkers, Tumor; D016159:Tumor Suppressor Protein p53